Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer

Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer

Abstract Bevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colorectal cancer (mCRC), however to date no predictive factors of response have been identified. Results of our previous analysis on patients enrolled in a randomized prospective phase III multicenter stud...

Full description

Bibliographic Details
Main Authors: Giorgia Marisi, Irene Azzali, Alessandro Passardi, Francesca Rebuzzi, Giulia Bartolini, Milena Urbini, Matteo Canale, Chiara Molinari, Laura Matteucci, Francesco Giulio Sullo, Silvia Angela Debonis, Chiara Gallio, Graziana Gallo, Giovanni Luca Frassineti, Paola Ulivi
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-40220-7

Internet

https://doi.org/10.1038/s41598-023-40220-7

Similar Items